Research programme: small-molecule antivirals - Kemin Pharma/USAMRIID

Drug Profile

Research programme: small-molecule antivirals - Kemin Pharma/USAMRIID

Alternative Names: KPE00001175

Latest Information Update: 23 Sep 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kemin Pharma
  • Developer United States Army Medical Research Institute of Infectious Diseases
  • Class Carbohydrates; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronavirus infections; Smallpox

Most Recent Events

  • 23 Sep 2008 Discontinued - Preclinical for Coronavirus infections in Belgium (unspecified route)
  • 23 Sep 2008 Discontinued - Preclinical for Coronavirus infections in USA (unspecified route)
  • 23 Sep 2008 Discontinued - Preclinical for Smallpox in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top